Glucocerebrosidase (GBA) mutations have been associated with Parkinson’s disease in
numerous studies. However, it is unknown whether the increased risk of Parkinson’s disease in …

Importance Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has
been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine …

… Levodopa is available in an orally dissolving tablet that does not require water. Controlled
released levodopa in the form of sinemet and madopar is also available, and can be …

Objective: To evaluate the nonergot dopamine agonist ropinirole as an adjunct to L-dopa in
a randomized, double-blind trial in PD patients with motor fluctuations. Background: L-dopa …

Little is known about the underlying dimensions of impaired recognition of emotional prosody
that is frequently observed in patients with Parkinson's disease (PD). Because patients …

In this double-blind, placebo-controlled trial, we investigated the effect of the catechol-O-methyltransferase
inhibitor tolcapone 100 or 200 mg three times daily on activities of daily living …

Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This
minimizes first‐pass metabolism and provides high plasma concentrations of selegiline. In …

… CH Waters at Division of Movement Disorders, USC School of Medicine, 1510 San Pablo …
Acknowledgment: This work was funded by a grant from the Southern California Chapter of the …

… Disclosure: Cheryl H Waters has disclosed the following relevant financial relationships: …
Based on the review by Drs Wright and Waters, which of the following statements about …

… Cheryl Waters reports receiving consultation fees from Prophase, Lundbek, Impax and
Acorda. Karen Marder reports grants from NIH [NS036630 (PI), 1UL1 RR024156-01 (Director …